Relationship Between C. Difficile Toxins' Serum Level With C. Difficile Infection
NCT03586206 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 45
Last updated 2018-07-13
Summary
To assess the association between Clostridium difficile (CD) toxins' serum levels and the grade of Clostridium difficile infection (CDI) severity/failure to CDI treatment and rate of recurrence. Furthermore, the kinetics of CD toxins in serum of CDI patients undergoing anti-CDI treatment, as well as the relationship between serum toxins levels and length of CDI diarrhea will be evaluated.
Conditions
- Clostridium Difficile
- Clostridium Difficile Infection
Sponsors & Collaborators
- collaborator INDUSTRY
-
Roma Tre University
lead OTHER
Eligibility
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2018-09-15
- Primary Completion
- 2019-09-15
- Completion
- 2020-12-31
More Related Trials
-
Novel Biomarkers to Predict Outcome in Clostridium Difficile Infection
NCT02086916 ·Status: COMPLETED
-
Changes in Recipients Gut Microbiota After Fecal Microbiota Transplantation
NCT05739825 ·Status: RECRUITING
-
Ursodeoxycholic Acid in C. Difficile Infection
NCT05526807 ·Status: TERMINATED ·Phase: NA
-
Safety and Efficacy Study of VP20621 for Prevention of Recurrent Clostridium Difficile Infection
NCT01259726 ·Status: COMPLETED ·Phase: PHASE2
-
Host Immune Response to Clostridium Difficile Infection (ICD)
NCT02440438 ·Status: COMPLETED ·Phase: NA
-
C.Difficile Observational Study
NCT06277999 ·Status: COMPLETED
-
The Role of Mucosal Microbiome in the Development, Clearance and Recurrence of Clostridioides Difficile Infection
NCT04679324 ·Status: WITHDRAWN
-
Evaluation of Gut Microbiota and Its Associated Resistome in FMT Donors and Recipients Due to Recurrent Clostridiodes Difficile Infection
NCT06533800 ·Status: NOT_YET_RECRUITING
-
The Role of Mucosal Microbiome in Recurrence of Clostridioides Difficile Infection
NCT04675723 ·Status: COMPLETED
-
Immune Response to C.Difficile Infection
NCT02797288 ·Status: UNKNOWN
-
Study of Different Formulations of a Clostridium Difficile Toxoid Vaccine Given at Three Different Schedules in Adults
NCT01230957 ·Status: COMPLETED ·Phase: PHASE2
-
Study of a Candidate Clostridium Difficile Toxoid Vaccine in Subjects at Risk for C. Difficile Infection
NCT01887912 ·Status: TERMINATED ·Phase: PHASE3
-
PROSPECTIVE STUDY OF PREDISPOSING FACTORS OF REFRACTARY Clostridium Difficile INFECTION. INFLUENCE OF THE GUT MICROBIOMA
NCT04259931 ·Status: UNKNOWN
-
Descriptive Epidemiology of Clostridium Difficile Infection in Hospitalized Adult Patients in the Asia Pacific Region
NCT01560832 ·Status: COMPLETED
-
SER-262 Versus Placebo in Adults With Primary Clostridium Difficile Infection to Prevent Recurrence
NCT02830542 ·Status: COMPLETED ·Phase: PHASE1
-
Study on Clostridium Difficile Infection in Infants
NCT06703918 ·Status: RECRUITING
-
Personalized Needs in Clostridium Difficile Infections
NCT02573571 ·Status: COMPLETED
-
Vancomycin Prophylaxis in Recurrent Clostridium Difficile Infection
NCT02237859 ·Status: UNKNOWN ·Phase: PHASE4
-
AssessmeNT of the Incidence of Clostridium Difficile Infections in Hospitalized Patients on Antibiotic TrEatment
NCT02896244 ·Status: COMPLETED
-
FMT in Patients With Recurrent CDI and Ulcerative Colitis: Single Infusion Versus Sequential Approach
NCT06071312 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Oral Vancomycin for Secondary Prophylaxis of Clostridium Difficile Infection (CDI)
NCT04000555 ·Status: TERMINATED ·Phase: PHASE4
-
Study of Clostridioides Difficile in Infants
NCT06788769 ·Status: RECRUITING
-
Association Between Response to Treatment of C. Diff Colitis and Anti-C.Diff Toxin Antibody
NCT00304408 ·Status: COMPLETED
-
TOX NEG Trial: Clostridium Difficile Diagnosis and Treatment
NCT03388268 ·Status: COMPLETED ·Phase: PHASE4
-
Secondary Prevention of Clostridioides Difficile Using Vancomycin
NCT06979609 ·Status: RECRUITING ·Phase: PHASE2/PHASE3